Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of four essential trace elements—zinc sulfate, cupric sulfate, manganese sulfate, and selenious acid—formulated for intravenous administration as a supplement to parenteral nutrition (PN). It is indicated for adult and pediatric patients, including neonates, who require long-term parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Each component serves as a critical cofactor for various metabolic processes: zinc is essential for protein synthesis and cell division; copper is a cofactor for enzymes like cytochrome c oxidase; manganese activates enzymes such as decarboxylases and kinases; and selenium is a component of glutathione peroxidase, which protects cells from oxidative stress. The combination was developed to provide a standardized source of these elements, reducing the risk of contamination and dosing errors associated with manual compounding of individual trace elements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc sulfate + cupric sulfate + manganese sulfate + selenious acid.